Physicochemical Properties
| Molecular Formula | C8H12INO |
| Molecular Weight | 265.0945 |
| Exact Mass | 264.996 |
| CAS # | 930800-38-7 |
| Related CAS # | 124-87-8; |
| PubChem CID | 44448710 |
| Appearance | White to off-white solid powder |
| LogP | 2.181 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 11 |
| Complexity | 159 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | YCRUVTMZPHEOAM-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C8H12INO/c1-2-3-4-5-6-10-8(11)7-9/h1H,3-7H2,(H,10,11) |
| Chemical Name | N-hex-5-ynyl-2-iodoacetamide |
| Synonyms | IA alkyne IAalkyne IA-alkyne |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Cysteine and IA-Alkyne (2.5–10 μM; 1 hour) react. IA-Alkyne was used to treat the soluble fraction of HeLa internal cells (2.0 mg/mL). Conjugation of CuAAC to hydrophobic tags of fluorescent rhodamine-labeled proteome samples was used for analysis, followed by SDS-PAGE folding. The highest fluorescence intensity is found in IA-Alkyne, according to fluorescence imaging inside the hydrophobicity [2]. |
| References |
[1]. David L. Use of trp channel agonists to treat infections. Patent US20130203715A1. [2]. Inhibition by iodoacetamide and acetylene of the H-D-exchange reaction catalyzed by Thiocapsa roseopersicina hydrogenase. Eur J Biochem. 1996 Oct 15;241(2):675-81. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~377.23 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7723 mL | 18.8615 mL | 37.7230 mL | |
| 5 mM | 0.7545 mL | 3.7723 mL | 7.5446 mL | |
| 10 mM | 0.3772 mL | 1.8862 mL | 3.7723 mL |